Phase II Trial of Blinatumomab in Patients with Relapsed or Refractory DLBCL


Phase II Trial of Blinatumomab in Patients with Relapsed or Refractory DLBCL
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Stephen M Ansell, MD, PhD (1/20/15)
Viardot A et al. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T-cell engager (BiTE®) antibody construct blinatumomab: Primary analysis results from an open-label, phase 2 study. Proc ASH 2014;Abstract 4460.

Dr Ansell is Professor of Medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota.